Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study.

@article{Ellis2009LowerdoseVH,
  title={Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study.},
  author={Matthew J. Ellis and Feng Gao and Farrokh Dehdashti and Donna B. Jeffe and Paul Kelly Marcom and Lisa A. Carey and Maura N. Dickler and Paula Silverman and Gini F. Fleming and Aruna Kommareddy and Shohreh Jamalabadi-Majidi and Robert Crowder and Barry A. Siegel},
  journal={JAMA},
  year={2009},
  volume={302 7},
  pages={774-80}
}
CONTEXT Estrogen deprivation therapy with aromatase inhibitors has been hypothesized to paradoxically sensitize hormone-receptor-positive breast cancer tumor cells to low-dose estradiol therapy. OBJECTIVE To determine whether 6 mg of estradiol (daily) is a viable therapy for postmenopausal women with advanced aromatase inhibitor-resistant hormone receptor-positive breast cancer. DESIGN, SETTING, AND PATIENTS A phase 2 randomized trial of 6 mg vs 30 mg of oral estradiol used daily (April… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 4 times over the past 90 days. VIEW TWEETS
101 Citations
15 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 101 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 15 references

Similar Papers

Loading similar papers…